(a).
| Follicular lymphoma 1031 studies |
Monoclonal antibodies 232 studies |
Anti-PD-1 | 2 studies | Combination with rituximab |
| CD20 radio | 34 studies | Combination | ||
| immunotherapy | including | + ASCT | ||
| Phase 3 | ||||
| CD45 131I | 1 study | + ASCT | ||
| Phase 2 | ||||
| Anti-CTLA-4 | 1 study | Combination with SD- | ||
| 101 (TLR9 agonist) | ||||
| Anti-CD20 | 10 studies | + lenalidomide | ||
| Phase 1 | maintenance | |||
| Phase 2 | ||||
| Bevacizumab | Phase 1 | Combination | ||
| Phase 1 | + vandetanib | |||
| Apolizumab | Phase 1 | |||
| (anti-DR) | Phase 2 | |||
| Galiximab (anti-CD80) | Phase 2 1 study |
+ rituximab | ||
| Anti-CD19 | Phase 1 | |||
| 2 studies | ||||
| Anti-CD22 | Phase 1/2 | + ASCT | ||
| Radioimmunotherapy | Phase 2/3 | |||
| Cold | Phase 1 | |||
| Anti-CD74 | Phase 1/2 | Combination with rituximab | ||
| Anti-CD20+IL12 | ||||
| Anti-αvβ3 integrin | Phase 1 | |||
| Anti-CD80 | Phase 1/2 | |||
| BMK120 | Phase 1 | Rituximab | ||
| Buparlisib | ||||
| PI3K inhibitor | BAY80-6946 | Phase 2 | ||
| Idelalisib | Phase 3 | Combination | ||
| Entospletinib | Phase 1 | |||
| BTK inhibitor | Ibrutinib/ONO 4059 Spebrutinib |
Phase 2 |
10 studies |
|
| Anti-CDK | Flavopiridol | Phase 1 | Combination | |
| Antisense | Phase 2 | Combination with rituximab | ||
| Anti-Bcl-2 | 2 studies | |||
| Obatoclax | Phase 1/2 | |||
| Anti-PARP | Alisertib Veliparib |
Phase 2 Phase 1/2 |
Combination |
|
| HDAC | Vorinostat | Phase 2 | + rituximab | |
| Anti-kinase | Vandetanib | Phase 1 |